Therapeutic Drug Monitoring in Patients with Ulcerative Colitis on Infliximab: A Cost-Effectiveness Analysis

Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778.

Article  PubMed  Google Scholar 

Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453–455.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–1201.

Article  CAS  PubMed  Google Scholar 

Roda G, Jharap B, Neeraj N et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roblin X, Marotte H, Leclerc M et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis. 2015;9:525–531.

Article  CAS  PubMed  Google Scholar 

Vande Casteele N, Ferrante M, Van Assche G et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-1329.e1323.

Article  CAS  PubMed  Google Scholar 

Fernandes SR, Bernardo S, Simões C et al. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease. Inflamm Bowel Dis. 2020;26:263–270.

Article  PubMed  Google Scholar 

Syed N, Tolaymat M, Brown SA et al. Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab reatment and lower healthcare utilization compared with reactive and clinical monitoring. Crohns Colitis 360 2020;2:50. (Author names in bold designate shared co-first authorship)

Google Scholar 

Shah R, Hoffman GR, El-Dallal M et al. Is therapeutic drug monitoring for anti-tumour necrosis factor agents in adults with inflammatory bowel disease ready for standard of care? A systematic review and meta-analysis. J Crohns Colitis. 2020;14:1057–1065. (Author names in bold designate shared co-first authorship)

Article  PubMed  Google Scholar 

Papamichael K, Chachu KA, Vajravelu RK et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15:1580-1588.e1583.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feuerstein JD, Nguyen GC, Kupfer SS et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827–834.

Article  PubMed  Google Scholar 

Negoescu DM, Enns EA, Swanhorst B et al. Proactive vs reactive therapeutic drug monitoring of infliximab in Crohn’s disease: a cost-effectiveness analysis in a simulated cohort. Inflamm Bowel Dis. 2020;26:103–111.

Article  PubMed  Google Scholar 

Ungar B, Chowers Y, Yavzori M et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258–1264.

Article  CAS  PubMed  Google Scholar 

Brun MK, Goll GL, Jørgensen KK et al. Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial. J Intern Med. 2022;292:477–491.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alarid-Escudero F, Krijkamp EM, Pechlivanoglou P et al. A need for change! a coding framework for improving transparency in decision modeling. Pharmacoeconomics. 2019;37:1329–1339.

Article  PubMed  PubMed Central  Google Scholar 

Arias E. United States life tables, 2006. Natl Vital Stat Rep. 2010;58:1–40.

PubMed  Google Scholar 

Agency for Healthcare Research and Quality. Number of people in thousands, United States, 1996–2018 Accessed at on 9 November 2023.

Nordenvall C, Ekbom A, Bottai M et al. Mortality after total colectomy in 3084 patients with inflammatory bowel disease: a population-based cohort study. Aliment Pharmacol Ther. 2014;40:280–287.

Article  CAS  PubMed  Google Scholar 

IBM Micromedex® Red Book, Truven Health Analytics (2021). .

Center for Medicare & Medicaid Services. Physician Fee Schedule Search.

Center for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule.

Weissman S, Sharma S, Fung BM et al. Increased mortality and healthcare costs upon hospital readmissions of ulcerative colitis flares: a large population-based cohort study. Crohns Colitis 360 2021;3:otab029. (Author names in bold designate shared co-first authorship)

Article  PubMed  PubMed Central  Google Scholar 

Holubar SD, Long KH, Loftus EV Jr et al. Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County. Minnesota. Dis Colon Rectum. 2009;52:1815–1823.

Article  PubMed  Google Scholar 

Chang AL, Kim Y, Ertel AE et al. Case mix-adjusted cost of colectomy at low-, middle-, and high-volume academic centers. Surgery. 2017;161:1405–1413.

Article  PubMed  Google Scholar 

Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ. 2010;11:67–76.

Article  PubMed  Google Scholar 

Hanmer J, Lawrence WF, Anderson JP et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26:391–400.

Article  PubMed  Google Scholar 

Sanders GD, Neumann PJ, Basu A et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093–1103.

Article  PubMed  Google Scholar 

Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res. 2018;53:175–196.

Article  PubMed  Google Scholar 

Agency for Healthcare Research and Quality. Using appropriate price indices for expenditure comparisons. Accessed at www.meps.ahrq.gov/about_meps/Price_Index.shtml on 9 November 2023.

Briggs AH, Weinstein MC, Fenwick EAL et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group–6. Med Decis Making. 2012;32:722–732.

Article  PubMed  Google Scholar 

Goldhaber-Fiebert JD, Jalal HJ. Some health states are better than others: using health state rank order to improve probabilistic analyses. Med Decis Making. 2016;36:927–940.

Article  PubMed  Google Scholar 

Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265.

Article  CAS  PubMed  Google Scholar 

Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–1214.

Article  CAS  PubMed  Google Scholar 

Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.

Article  CAS  PubMed  Google Scholar 

Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113–2128.

Article  CAS  PubMed  Google Scholar 

Papamichael K, Vajravelu RK, Vaughn BP et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis. 2018;12:804–810.

Article  PubMed  PubMed Central  Google Scholar 

Comments (0)

No login
gif